Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;21(11):2586-2593.
doi: 10.1038/s41436-019-0534-x. Epub 2019 May 21.

Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes

Affiliations
Free article

Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes

Deborah Schofield et al. Genet Med. 2019 Nov.
Free article

Abstract

Purpose: To undertake the first end-to-end cost-effectiveness analysis of exome sequencing (ES) in rare disease diagnosis.

Methods: A cohort of 80 infants who underwent ES and usual diagnostic care in parallel were used to model incremental cost and health outcomes (quality adjusted life-years, QALYs) attributable to ES diagnosis over a 20-year horizon. Three models were developed: (1) outcomes in patients only, (2) outcomes in patients and first-degree relatives as a result of cascade testing, and (3) outcomes in patients and first-degree relatives including parental reproductive outcomes.

Results: When the directly observed cost and health outcomes of the cohort participants were projected, the use of ES resulted in a gain of 7.39 QALYs and an incremental cost-effectiveness ratio (ICER) of AU$31,144.35 (i.e., cost per additional QALY gained). When cascade testing in first-degree relatives was added, cost-effectiveness increased, to a gain of 11.62 QALYs and an ICER of AU$20,839.57. When parental reproductive outcomes were added, cost-effectiveness increased again, with 36.00 QALYs gained and an ICER of AU$14,235.28.

Conclusion: Use of ES in suspected monogenic disorders becomes increasingly cost-effective as the benefits of ES data reanalysis, cascade testing in first-degree relatives, and parental reproductive outcomes are incorporated into modeling.

Keywords: ICER; QALY; cost-effectiveness; exome sequencing.

PubMed Disclaimer

Comment in

  • Economic value of exome sequencing for suspected monogenic disorders.
    Ferket BS, Veenstra DL. Ferket BS, et al. Genet Med. 2020 Nov;22(11):1909. doi: 10.1038/s41436-020-0888-0. Epub 2020 Jun 30. Genet Med. 2020. PMID: 32601385 No abstract available.
  • Response to Ferket et al.
    Schofield D, Rynehart L, Shresthra R, White SM, Stark Z. Schofield D, et al. Genet Med. 2020 Nov;22(11):1910. doi: 10.1038/s41436-020-0889-z. Epub 2020 Jul 1. Genet Med. 2020. PMID: 32606441 No abstract available.

References

    1. Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med. 2018;3:16. - DOI
    1. Hayeems RZ, Bhawra J, Tsiplova K, et al. Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray. Eur J Hum Genet. 2017;25:1303–1312. - DOI
    1. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20:112–1130. - DOI
    1. Vrijenhoek T, Middelburg EM, Monroe GR, et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur J Hum Genet. 2018;26:1566–1571. - DOI
    1. Stark Z, Schofield D, Alam K, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19:867–874. - DOI

LinkOut - more resources